Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study
Younak Choi, Do-Youn Oh, Kyubo Kim, Eui Kyu Chie, Tae-Yong Kim, Kyung-Hun Lee, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Sung Whan Ha, Yung-Jue Bang
Cancer Res Treat. 2016;48(3):1045-1055.   Published online 2015 Oct 16     DOI: https://doi.org/10.4143/crt.2015.226
Citations to this article as recorded by Crossref logo
Comparing concurrent chemoradiotherapy, 125 I seed implantation combined with chemotherapy, and chemotherapy alone efficacy in treating unresectable locally advanced pancreatic cancer
Yanfen Zheng, Rui Huang, Wenxue Zou, Chao Liu, Hongxin Niu, Jinbo Yue
Precision Radiation Oncology.2022; 6(2): 144.     CrossRef
Concurrent Nab-paclitaxel and Radiotherapy
William T. Arscott, Kevin T. Nead, Adham Bear, Sriram Venigalla, Jacob Shabason, John N. Lukens, John P. Plastaras, Andrzej Wojcieszynski, James Metz, Mark O’Hara, Kim A. Reiss, Ursina Teitelbaum, Arturo Loaiza-Bonilla, Jeffrey Drebin, Major K. Lee, Stuti
American Journal of Clinical Oncology.2021; 44(9): 469.     CrossRef
Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer
Mei Hua Jin, Ah-Rong Nam, Ji Eun Park, Ju-Hee Bang, Yung-Jue Bang, Do-Youn Oh
Cancer Research and Treatment.2020; 52(1): 149.     CrossRef
Current trends and issues of conversion surgery for patients with locally advanced unresectable pancreatic cancer
Toshimichi ASANO, Satoshi HIRANO, Toru NAKAMURA, Takehiro NOJI, Keisuke OKAMURA, Takahiro TSUCHIKAWA, Yuma EBIHARA, Toshiaki SHICHINOHE
Suizo.2018; 33(1): 48.     CrossRef
Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment
Toshimichi Asano, Satoshi Hirano, Toru Nakamura, Keisuke Okamura, Takahiro Tsuchikawa, Takehiro Noji, Yoshitsugu Nakanishi, Kimitaka Tanaka, Toshiaki Shichinohe
Journal of Hepato-Biliary-Pancreatic Sciences.2018; 25(7): 342.     CrossRef
Which patients with locally advanced pancreatic cancer treated with induction chemotherapy are most likely to benefit from post-induction chemoradiotherapy?
Sophie Otter, Irene Chong, Ria Kalaitzaki, Diana Tait
International Journal of Hepatobiliary and Pancreatic Diseases.2018; 8(1): 1.     CrossRef
Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy
Yi-Jun Kim, Hyeon Kang Koh, Eui Kyu Chie, Do-Youn Oh, Yung-Jue Bang, Eun Mi Nam, Kyubo Kim
International Journal of Clinical Oncology.2017; 22(6): 1069.     CrossRef
Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study
Dong S., Wang L., Guo Y. B., Ying H. F., Shen X. H., Meng Z. Q., Chen Hao, Chen Q. W., Li Z. S.
World Journal of Surgical Oncology.2017;[Epub]     CrossRef
Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma
Ilhan Karabicak, Sohei Satoi, Hiroaki Yanagimoto, Tomohisa Yamamoto, Satoshi Hirooka, So Yamaki, Hisashi Kosaka, Kentaro Inoue, Yoichi Matsui, Masanori Kon
Journal of Hepato-Biliary-Pancreatic Sciences.2016; 23(12): 750.     CrossRef